An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
Cardiovascular Systems, Inc. to Participate in Two November Healthcare Conferences
Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary
Cardiovascular Systems, Inc. (CSII) announced plans to participate in the Stifel 2022 Healthcare Conference on November 16, 2022, at 1:15 p.m. ET, where it will also host investor meetings. Additionally, the company will host investor meetings at the Canaccord Genuity MedTech Conference on November 17, 2022. CSII specializes in innovative treatment systems for vascular and coronary diseases, notably its orbital atherectomy system designed to treat calcified plaque in arterial vessels.
Positive
None.
Negative
None.
ST. PAUL, Minn.--(BUSINESS WIRE)--
Cardiovascular Systems, Inc. (CSI®) (NASDAQ: CSII), a medical device company developing and commercializing innovative interventional treatment systems for patients with peripheral and coronary artery disease, today announced that management plans to present and host investor meetings at the Stifel 2022 Healthcare Conference and will host investor meetings at the Canaccord Genuity MedTech Conference.
Stifel 2022 Healthcare Conference
Wednesday, November 16, 2022 1:15 p.m. ET Webcast
Canaccord Genuity MedTech Conference Thursday, November 17, 2022
About Cardiovascular Systems, Inc.
Cardiovascular Systems, Inc., based in St. Paul, Minn., is a medical device company focused on developing and commercializing innovative solutions for treating vascular and coronary disease. The company’s orbital atherectomy system treats calcified and fibrotic plaque in arterial vessels throughout the leg and heart and addresses many of the limitations associated with existing surgical, catheter and pharmacological treatment alternatives. For additional information, please visit www.csi360.com and connect on Twitter @csi360.
